Risks Associated with 5α-Reductase Inhibitor Use: Analysis of Adverse Drug Reactions Reported to EudraVigilance
Pharmaceuticals · 15.06.2026 · 19 (6) · 939
DOI: 10.3390/ph19060939 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 15.06.2026. Verfasst von Ricardo Alves und 2 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Health Sciences, University of Beira Interior, 6200-506 Covilhã, Portugal. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: FCT—Fundação para a Ciência e a Tecnologia.
Abstract (Originalsprache)
Background/Objectives: 5α-Reductase inhibitors (5ARIs) are commonly used to treat and prevent androgenic alopecia and benign prostatic hyperplasia. Despite their well-established effectiveness, they are associated with adverse drug reactions (ADRs), highlighting the need for continuous safety assessment. This study aimed to analyze the ADRs associated with finasteride and dutasteride, both as monotherapy and in combination therapy.
Methods
A retrospective analysis of ADRs associated with finasteride and dutasteride reported to EudraVigilance between 1 January 2005 and 27 March 2023 was performed. A total of 7777 reports were selected, and various variables were examined, including the temporal evolution of ADR reports, reporter profile, and the age group of the affected population. ADRs were categorized based on their seriousness and outcome, with particular focus on the most common reactions and their alignment with the Summary of Product Characteristics (SmPC).
Results
The most affected age group, excluding the “Not Specified” category, was “18–64 years.” Overall, finasteride was the most reported. The majority of reported ADRs were classified as “Serious,” with a predominant outcome of “Persists without recovery,” and a significant proportion of these ADRs were not listed in the respective 5ARI SmPCs. Among the ADRs classified as “Serious,” the most frequently reported seriousness criterion was “Clinically important”.
Conclusions
The results emphasize how crucial it is to continuously monitor these drugs in order to prevent and mitigate ADRs, ensure population safety, and promote public health. Additionally, more research is required to determine whether the ADRs not included in the SmPC could be new warning signs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Health Sciences, University of Beira Interior, 6200-506 Covilhã, Portugal.
- RISE-Health, Department of Chemistry, Faculty of Sciences, University of Beira Interior, 6201-001 Covilhã, Portugal.
- RISE-Health, Department of Medical Sciences, Faculty of Health Sciences, University of Beira Interior, 6200-506 Covilhã, Portugal.
- UFBI-Pharmacovigilance Unit of Beira Interior, Faculty of Health Sciences, University of Beira Interior, 6200-506 Covilhã, Portugal.
ORCID-Profile: Samuel Silvestre, Cristina Monteiro
Förderung
- FCT—Fundação para a Ciência e a Tecnologia
Zitieren
APA
Alves, R., Silvestre, S., & Monteiro, C. (2026). Risks Associated with 5α-Reductase Inhibitor Use: Analysis of Adverse Drug Reactions Reported to EudraVigilance. Pharmaceuticals, 19(6), 939. https://doi.org/10.3390/ph19060939
Vancouver
Alves R, Silvestre S, Monteiro C. Risks Associated with 5α-Reductase Inhibitor Use: Analysis of Adverse Drug Reactions Reported to EudraVigilance. Pharmaceuticals. 2026;19(6):939. doi:10.3390/ph19060939
BibTeX
@article{Alves2026,
author = {Alves, Ricardo and Silvestre, Samuel and Monteiro, Cristina},
title = {Risks Associated with 5α-Reductase Inhibitor Use: Analysis of Adverse Drug Reactions Reported to EudraVigilance},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {6},
pages = {939},
doi = {10.3390/ph19060939}
}
EUVIMED